Foon K A, Zighelboim J, Yale C, Gale R P
Blood. 1981 Sep;58(3):467-70.
One-hundred and seven patients with acute myelogenous leukemia (AML) ranging in age from 15 to 82 yr who were previously untreated, received a 70 day high-dose remission induction regimen consisting of daunorubicin, cytarabine, and thioguanine (TAD). Identical complete remission rates of 65% were observed for 33 patients 60 yr of age and older and for 74 patients age 15-59 yr. Median remission duration and survival were 14 mo and 22 mo for patients 60 yr and older, and 16 mo and 22 mo for patients 15-59 yr. These differences are not significant. These data indicate that older patients respond to intensive chemotherapy in a similar manner to younger patients with this disease.
107例年龄在15至82岁之间、既往未接受过治疗的急性髓性白血病（AML）患者接受了为期70天的高剂量缓解诱导方案，该方案由柔红霉素、阿糖胞苷和硫鸟嘌呤（TAD）组成。60岁及以上的33例患者和15至59岁的74例患者的完全缓解率均为65%。60岁及以上患者的中位缓解持续时间和生存期分别为14个月和22个月，15至59岁患者的中位缓解持续时间和生存期分别为16个月和22个月。这些差异不显著。这些数据表明，老年患者对强化化疗的反应与患有这种疾病的年轻患者相似。
